3788-16-7

Basic information

• Product Name: Cimemoxin
• Synonyms: Cimemoxin;Hydrazine, (cyclohexylmethyl)-
• CAS NO: 3788-16-7
• Molecular Formula: C₇H₁₆N₂
• Molecular Weight: 128.217
• Mol File: 3788-16-7.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 237.1°Cat760mmHg
• Flash Point: 111.1°C
• Appearance: /
• Density: 0.915g/cm³
• Vapor Pressure: 0.0456mmHg at 25°C
• Refractive Index: 1.476
• PKA: 8?+-.0.70(Predicted)
• CAS DataBase Reference: Cimemoxin(CAS DataBase Reference)
• NIST Chemistry Reference: Cimemoxin(3788-16-7)
• EPA Substance Registry System: Cimemoxin(3788-16-7)

Safety Data

• Hazardous Substances Data: 3788-16-7(Hazardous Substances Data)

Usage

General Description

Cimemoxin is a chemical compound that is used in the treatment of Alzheimer's disease. It has been found to inhibit the formation of amyloid plaques in the brain, which are associated with the progression of the disease. Cimemoxin also has antioxidant properties, which could help to protect and repair brain cells damaged by oxidative stress. Additionally, it has been shown to improve cognitive function and memory in animal studies. Overall, Cimemoxin has potential as a therapeutic agent for the treatment of Alzheimer's disease and other neurodegenerative disorders.

InChI:InChI=1/C7H16N2/c8-9-6-7-4-2-1-3-5-7/h7,9H,1-6,8H2

Upstream product

• 3637-60-3 N-Acetyl-N'-hexahydrobenzylhydrazin 
• 149267-56-1 N-1-(tert-butoxycarbonyl)-N-2-(cyclohexylmethyl)hydrazine 
• 2043-61-0 cyclohexanecarbaldehyde 
• 654058-77-2 N-((1Z)-1-aza-2-cyclohexylvinyl)(tert-butoxy)carboxamide 
• 3637-59-0 1,2,3,6-Tetrahydro-benzaldehyd-acethydrazon 
• 100-50-5 3-Cyclohexene-1-carboxaldehyde 

Downstream Products

• 17697-23-3 N,N'-Dibenzoyl-N-cyclohexylmethyl-hydrazin 
• 654058-81-8 methyl 1-(cyclohexylmethyl)-5-(4-methylthiophenyl)pyrazole-3-carboxylate 
• 654058-94-3 1-(cyclohexylmethyl)-5-(4-methylthiophenyl)pyrazole-3-carbaldehyde 
• 654058-83-0 (1-(cyclohexylmethyl)-5-(4-methylthiophenyl)pyrazol-3-yl)methanol 
• 654058-48-7 [1-cyclohexylmethyl-5-(4-methanesulfonyl-phenyl)-1H-pyrazol-3-yl]-methanol 
• 654058-96-5 (2E)-3-(1-(cyclohexylmethyl)-5-(4-methylthiophenyl)pyrazol-3-yl)prop-2-en-ol-1 
• 654058-98-7 3-(1-(cyclohexylmethyl)-5-(4-methylthiophenyl)pyrazol-3-yl)propan-1-ol 
• 654058-95-4 methyl (2E)-3-[1-(cyclohexylmethyl)-5-(4-methylthiophenyl)pyrazol-3-yl]prop-2-enoate 
• 654058-52-3 1-(3-((1E)-3-hydroxyprop-1-enyl)1-(cyclohexylmethyl)pyrazol-5-yl)-4-(methylsulfonyl)benzene 
• 654058-53-4 3-[1-cyclohexylmethyl-5-(4-methanesulfonyl-phenyl)-1H-pyrazol-3-yl]-propan-1-ol 
• 1561965-95-4 ethyl 5-(4-(N-(tert-butyl)sulfamoyl)-2,3-dichlorophenyl)-1-(cyclohexylmethyl)-1H-pyrazole-3-carboxylate 
• 957507-55-0 C₁₁H₁₉N₃ 

Relevant articles and documents

Discovery, synthesis and characterization of a series of (1-alkyl-3-methyl-1H-pyrazol-5-yl)-2-(5-aryl-2H-tetrazol-2-yl)acetamides as novel GIRK1/2 potassium channel activators

The present study describes the discovery and characterization of a series of 5-aryl-2H-tetrazol-3-ylacetamides as G protein-gated inwardly-rectifying potassium (GIRK) channels activators. Working from an initial hit discovered during a high-throughput screening campaign, we identified a tetrazole scaffold that shifts away from the previously reported urea-based scaffolds while remaining effective GIRK1/2 channel activators. In addition, we evaluated the compounds in Tier 1 DMPK assays and have identified a (3-methyl-1H-pyrazol-1-yl)tetrahydrothiophene-1,1-dioxide head group that imparts interesting and unexpected microsomal stability compared to previously-reported pyrazole head groups.